Wednesday 6-18-2014 Gilead Sciences (GILD) $GILD opened at

New Post Public Reply Private Reply Replies (0) Message Board

Jun 18, 2014 at 9:25 PM

Wednesday 6-18-2014 Gilead Sciences (GILD) $GILD opened at 79.85 hitting the high price of 79.99 and a day low of 78.83 with a total volume of 12,003,035. GILD had a previous close of 79.79 and has been seeing an average volume of 10,232,540.

Overall Average: 8% Sell

Recent stock forum discussions about GILD http://investorshangout.com/search?q=GILD&...mp;yt0=Go!

Growing Insurer Centene Embraces Affordable Care Act
at Investor's Business Daily - 2 hrs 50 mins ago
The Affordable Care Act (ACA) has taken its share of criticism since its October launch, but health insurer Centene (CNC) is poised for strong growth because of it. The company's primary focus is the Medicaid managed-care business, which it conducts... (full story)

Merck KGaA-Ono Pharma Deal Ends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 5:15PM CDT
Merck KGaA (MKGAF) has decided to terminate its license agreement with Ono Pharma related to the development of Ono Pharma's multiple sclerosis candidate, ceralifimod (ONO-4641). (full story)

Final Glance: Biotechnology companies
AP - Wed Jun 18, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)

Biogen/AbbVie Presents Positive Data on Daclizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 4:03PM CDT
Biogen Idec (BIIB) and partner AbbVie (ABBV) announced positive top-line results from a phase III trial, DECIDE, on pipeline candidate, daclizumab. (full story)

Midday Glance: Biotechnology companies
AP - Wed Jun 18, 1:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.: (full story)

Early Glance: Biotechnology companies
AP - Wed Jun 18, 10:36AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)

Alexion's Soliris Gets Orphan Drug Status for New Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 10:30AM CDT
The FDA granted Alexion's (ALXN) Soliris Orphan Drug Status for MG. (full story)

Pfizer Ties Up with Cellectis for Cancer Immunotherapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 10:10AM CDT
Pfizer entered into an agreement with Cellectis to develop chimeric antigen receptor CAR-T immunotherapies directed at select targets. (full story)

AVEO Pharmaceuticals (AVEO) Catches Eye: Stock Up 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 8:46AM CDT
AVEO Pharmaceuticals (AVEO) was a big mover last session, with shares rising over 11% on the day. (full story)

The Zacks Analyst Blog Highlights: DreamWorks Animation, Netflix, Valeant Pharmaceuticals International, Allergan, Gilead Sciences and ForestLaboratories
PR Newswire - Wed Jun 18, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the DreamWorks Animation SKG Inc. (Nasdaq

WA-Free Report), Netflix Inc. (Nasdaq:NFLX-Free Report), News Corp. (Nasdaq:NWSA-Free Report), Valeant Pharmaceuticals International, Inc. (NYSE:VRX-Free Report), Allergan, Inc. (NYSE:AGN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report) and Forest Laboratories Inc. (NYSE:FRX-Free Report). (full story)

Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry
at Investor's Business Daily - Wed Jun 18, 7:02AM CDT
With 2014 already the strongest year for mergers and acquisitions since 2007, the flurry of dealmaking has given shares of some large drugmakers a shot in the arm -- or face, in the case of Botox maker Allergan (AGN). But not all offers have been... (full story)

Is This Gilead's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 17, 4:30PM CDT
It's not often that big name biotechs double their earnings year over year. Yet that's exactly what Gilead Sciences did in the first quarter of 2014 after posting record sales for its new hepatitis C drug Sovaldi. Sovaldi raked in a reported... (full story)

J&J's Velcade in Focus at the European Hematology Association - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 4:20PM CDT
Johnson & Johnson (JNJ) presented encouraging data from a phase III study on its oncology drug, Velcade, at the annual meeting of the European Hematology Association. (full story)

Vertex Pharmaceuticals Crumbles on Analyst Worries - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 4:00PM CDT
An analyst estimates that two pivotal phase III studies (TRAFFIC and TRANSPORT) on Vertex Pharmaceuticals Incorporated's (VRTX) combination cystic fibrosis therapy are more likely to fail. (full story)

Novartis Submits Bexsero to FDA for Marketing Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 3:47PM CDT
Novartis (NVS) announced the submission of its BLA for meningitis B vaccine candidate Bexsero to the FDA for marketing approval among adolescents and young adults within the age group of 10 to 25 years. (full story)

Glaxo's Promacta Holds Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 3:45PM CDT
GlaxoSmithKline (GSK) announced encouraging results from the phase III PETIT2 study on Promacta. (full story)

After Yesterday's Decline of 1.21%, Gilead Sciences Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 17, 3:39PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $79.56 to a high of $80.87. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $79.87 on volume of 11.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)

SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 1.21% Loss
Comtex SmarTrend(R) - Tue Jun 17, 3:38PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $79.56 to a high of $80.87. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $79.87 on volume of 11.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)

Ligand Pharma's LGD-6972 Positive in Phase I Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 3:35PM CDT
Ligand Pharmaceuticals Inc. (LGND) announced positive data from a phase I study on its type II diabetes candidate, LGD-6972. (full story)

Gilead Sciences Inc. (GILD) Stock Research Links

GILD Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASCEND® Cladding Unveils New Profiles & Texture Variety

New Options for Creative Home Exteriors Amid today's housing market rollercoaster, a sprinkle of bold innovation in building materials can make a statement—and that's precisely what Associated Materials Innovations (AMI) is banking on with their latest beef-up in the ASCEND® Composite Cladding lineup. Introduced out of Cuyahoga Falls on Sept. 8, 2026, this expansion...

Hanover Unveils Skinny Veg® for GLP-1 Dieters

Seems like Hanover Foods is turning heads with their move into the ever-demanding health-conscious market. This family's stepping into the limelight with their new Skinny Veg® line, clearly targeting folks riding the GLP-1 wave. You see, it's not every day that a company that's been around the block since 1924 shakes things up like this. Simplicity is the Name of the...

AI Startup Shuttlebase Navigates Name Clash with Change

When Two AI Giants Collide Every so often, we get a clash of titans in the business world, and this time it's in the AI universe. New York's Moonshot AI, a champ in autonomous website optimization, hit a bump when its name collided with a Chinese counterpart, also called Moonshot AI. And just like that, the NY company had to chuck their name out the window and don a new...

IDX Expands, Enhances Team Amid 56% H1 Growth

IDX's Aggressive Global Expansion Here's a tip from a trader who’s seen cycles rise and fall: watch the movers who're playing the long game, putting down roots worldwide while making headway in the data game. IDX has clearly mapped out this trajectory as evidenced by its recent grab in the global strategic communications ring. IDX's bustling around like a squirrel...

Muscle Car Fever Revs Up in New Global TV Series

Chasing the Dream on Wheels Amid the buzz of New York, there's a roar building up that's hard to ignore. It's a sound that echoes through time, capturing the imagination of petrol heads everywhere—those legendary American muscle cars are back in the limelight. I mean, who hasn't dreamt of launching down a highway in a '69 Ford Mustang? 'The Hunt for Rolling Treasure' is...

How Timekettle Is Bridging Language Gaps at IFA 2026

Pioneering AI Innovations in Language Translation Timekettle is making some serious waves at IFA 2026, throwing its hat in the ring with innovations that redefine multilingual interaction. From sleek translation earbuds to full-blown meeting hubs, each gadget screams one thing loud and clear—communication sans language barriers. Centered in the tech extravaganza of...

Big Wins at Americas Cardroom's $15M Venom Series

High Stakes and Huge Paydays: The Venom Breakdown Alright, folks, here's a tale of how the cards fell in one of the most electrifying poker standoffs at Americas Cardroom. With prize pools clocking in at a staggering $15.095 million, the Dual Mystery Bounty Venoms really stacked the chips high. From the gritty, bustling halls of the internet to the proverbial green-felt...

Goodwill's ReThink Fashion: Textiles to Runway Art

Transforming Old to New on the Runway Right when you think fashion's all about the next shiny thing, here comes Goodwill of Delaware & Delaware County flipping the script. Their ReThink Fashion Show - the ECO Edit teaches us a thing or two about what giving old clothes a new life truly means. It's not just about tossing a used tee onto a catwalk but a whole rebirth...

Illinois' Legal Tangle: Feds Under Fire?

What a tangled web Illinois lawmakers have woven this time. They've gone and cooked up a pair of laws with a real knack for attracting attention—specifically from the folks over at the National Police Association (NPA). These aren’t your run-of-the-mill rules; they feel more like a blueprint for putting federal officers through the legal wringer and turning courtroom...

India's First Upright Proton Therapy System Unveiled

A Leap Forward in Cancer Care: Proton Therapy Revolution Dang, just when you think you've heard it all in cancer treatment, Fortis Healthcare drops a bombshell: India’s first upright proton therapy system. Boom! This isn't your run-of-the-mill radiation treatment we're talking about here. This is the futuristic flair of the MEVION S250-FIT™, featuring upright...